An announcement from Marker Therapeutics Inc (MRKR) is now available.
Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincoln Park Capital Fund, effective March 1, 2024, citing sufficient financial runway until the fourth quarter of 2025, negating the immediate need for further capital. Under the now-terminated agreement, Marker Therapeutics had the option to sell up to $25 million in common stock to LPC and had previously issued shares as a commitment. With no penalties for the early termination and no other significant relationships besides the agreement and associated registration rights, the company has fulfilled its obligations, including filing necessary documents with the SEC for the resale of its common stock.
See more data about MRKR stock on TipRanks’ Stock Analysis page.
